DataSheet1_A Necroptosis-Related lncRNA Signature Predicts Prognosis and Indicates the Immune Microenvironment in Soft Tissue Sarcomas.zip

Background: The necroptosis and long noncoding RNA (lncRNA) are critical in the occurrence and development of malignancy, while the association between the necroptosis-related lncRNAs (NRlncRNAs) and soft tissue sarcoma (STS) remains controversial. Therefore, the present study aims to construct a novel signature based on NRlncRNAs to predict the prognosis of STS patients and investigate its possible role.Methods: The transcriptome data and clinical characteristics were extracted from The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression database (GTEx). A novel NRlncRNA signature was established and verified by the COX regression analysis and least absolute shrinkage and selection operator (LASSO) regression analysis. Subsequently, the K-M survival analysis, ROC, univariate, multivariate Cox regression analysis, and nomogram were used to evaluate the predictive value of the signature. Also, a variety of bioinformatic analysis algorithms explored the differences between the potential mechanism, tumor immune status, and drug sensitivity in the two-risk group. Finally, the RT-qPCR was performed to evaluate the expression of signature NRlncRNAs.Results: A novel signature consisting of seven NRlncRNAs was successfully established and verified with stable prediction performance and general applicability for STS. Next, the GSEA showed that the patients in the high-risk group were mainly enriched with tumor-related pathways, while the low-risk patients were significantly involved in immune-related pathways. In parallel, we found that the STS patients in the low-risk group had a better immune status than that in the high-risk group. Additionally, there were significant differences in the sensitivity to anti-tumor agents between the two groups. Finally, the RT-qPCR results indicated that these signature NRlncRNAs were abnormally expressed in STS.Conclusion: To the best of our knowledge, it is the first study to construct an NRlncRNA signature for STS. More importantly, the novel signature displays stable value and translational potential for predicting prognosis, tumor immunogenicity, and therapeutic response in STS.</p

A summary of HRs for the overall and subgroup analyses of CRP levels in patients with bone neoplasms.

A summary of HRs for the overall and subgroup analyses of CRP levels in patients with bone neoplasms.</p

Prognostic value of C-reactive protein levels in patients with bone neoplasms: A meta-analysis

<div><p>Objective</p><p>The aim of this study was to conduct a meta-analysis of retrospective studies that investigated the association of preoperative C-reactive protein (CRP) levels with the overall survival (OS) of patients with bone neoplasms.</p><p>Methods</p><p>A detailed literature search was performed in the Cochrane Library, Web of Science, Embase and PubMed databases up to August 28, 2017, for related research publications written in English. We extracted the data from these studies and combined the hazard ratios (HR) and 95% confidence intervals (CIs) to assess the correlation between CRP levels and OS in patients with bone neoplasms.</p><p>Results</p><p>Five studies with a total of 816 participants from several countries were enrolled in this current meta-analysis. In a pooled analysis of all the publications, increased serum CRP levels had an adverse prognostic effect on the overall survival of patients with bone neoplasms. However, the combined data showed no significant relationship between the level of CRP and OS in Asian patients (HR = 1.73; 95% CI: 0.86–3.49; P = 0.125). Similar trends were observed in patients with bone neoplasms when stratified by ethnicity, histology, metastasis and study sample size.</p><p>Conclusions</p><p>The results of this meta-analysis suggest that increased CRP expression indicates a poorer prognosis in patients with bone neoplasms. More prospective studies are needed to confirm the prognostic significance of CRP levels in patients with bone neoplasms.</p></div

Forest plot of the association between the level of CRP and OS in patients with bone neoplasms stratified by ethnicity (A), histology (B), metastasis (C) and sample size (D).

<p>Summary of estimated hazard ratios (HRs) and 95% CI for patients stratified by (A) ethnicity, (B) histology, (C) metastasis and (D) sample size.</p

Flow chart of the study selection.

<p>Flow chart of the study selection.</p

Characteristics of all included studies.

<p>Characteristics of all included studies.</p

Begg’s funnel plot of the publication bias test for CRP level and OS in bone neoplasms.

<p>Summary of funnel plots of publication bias for the included studies. They are funnel plots of the publication bias for this meta-analysis of hazard ratios (HRs).</p

Forest plot of the association between the level of CRP and OS in patients with bone neoplasms.

<p>Summary of estimated hazard ratios (HRs) and 95% CI for patients with bone neoplasms.</p

Sensitivity analysis of the relationship between CRP level and OS in bone neoplasms.

<p>Sensitivity analyses were performed by excluding each study individually from the meta-analysis.</p

Additional file 1 of Identification of candidate genes and chemicals associated with osteoarthritis by transcriptome-wide association study and chemical-gene interaction analysis

Additional file 1